This route has been exploited artificially to deliver a drug payload to NRP1‐expressing cancer cells by attachment of an iRGD peptide to NRP1 and so initiate tumor cell killing (Teesalu et al, 2009; Kim et al, 2016). The gene discussed is NRP1; the disease is neoplasm.